MSFT 414.2162 -0.3066% AAPL 228.5 -0.2183% NVDA 146.7395 0.5823% GOOGL 167.89 -4.5971% GOOG 169.5501 -4.3872% AMZN 198.38 -2.2181% META 563.1866 -0.4126% BRK-A 564000.0 1.0181% BRK-B 371.74 0.9998% AVGO 164.04 0.4839% TSLA 340.34 -0.4941% TSM 190.62 1.1998% LLY 748.98 -0.588% V 309.9 0.8166% JPM 244.85 1.6903% UNH 597.49 -0.5012% NVO 102.79 -2.3558% WMT 88.39 1.3879% LVMUY 120.53 -0.9044% XOM 122.0297 1.421%
Section 1: Company Fundamentals
1.1 Company Overview and Performance summary
Company Overview:
Abbott Laboratories (NYE: ABT) is a global healthcare company. The Company’s portfolio of technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
This US Inflation Report covers the Company Overview & Price performance, Summary table, Key positives & negatives, Key metrics, Company details, technical guidance & Stock recommendation, and Price chart.
Price Performance:
1.2 Summary Table
1.3 The Key Positives & Negatives
1.4 Key Metrics
ABT has adeptly controlled its expenditures, effectively preserving revenue stability amidst periods of escalating global inflation. This strategic approach has yielded superior net margins when compared to industry peers. Notably, ABT has made significant strides in augmenting its Return on Equity (ROE) over the preceding year. This judicious financial management underscores ABT's resilience in navigating economic challenges, safeguarding profitability, and securing a favorable position within the competitive landscape. Through the optimization of spending and the fortification of revenue streams, the company has not only upheld its financial well-being but has also enhanced its profitability metrics, as evidenced by the improved ROE. This attests to ABT's unwavering commitment to delivering value to shareholders while effectively confronting economic uncertainties.
Section 2: Abbott laboratories (“Buy” at the closing market price of USD 112.45, as of January 25, 2024)
2.1 Company Details
2.2 Technical Guidance and Stock Recommendation
Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is January 25, 2024. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: The report publishing date is as per the Pacific Time Zone.
Technical Indicators Defined: -
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Resistance: A level at which the stocks prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.
Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.
Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.